Clinical trials: Degenerative Neurologic Disease
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease in which motor neuron cells of the brain and spinal cord progressively degenerate and die.
- Trial name
- ALS QoL (NCT07491484)
- Testing
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- TidalHealth, Inc.
Alzheimer Disease, CAREGİVER
The Progressively Lowered Stress Threshold Model
Today, with the prolongation of human life, the elderly population has increased and the frequency of diseases seen in old age has increased due to this situation. The most common of these diseases is Alzheimer's disease.
- Trial name
- NCT04305652
- Testing
- The Progressively Lowered Stress Threshold Model
- Where
- Turkey (Türkiye)
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Aksaray University
Spinocerebellar Ataxia 3
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3
There are no clinically established treatments which have been proven to delay the disease progression in spinocerebellar ataxia (SCA) 3.
- Trial name
- NCT04426149
- Testing
- trehalose
- Where
- Malaysia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Alzheimer's Disease, Aging
aeRobic Exercise and Cognitive Health
The purpose of the aeRobic Exercise and Cognitive Health (REACH) study is to understand how an aerobic exercise intervention might help promote brain health and cognition, thereby delaying the onset of clinical symptoms of…
- Trial name
- REACH (NCT02384993)
- Testing
- Enhanced Physical Activity
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Parkinson Disease
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease
This study will use single photon emission computed tomography, or SPECT (see below), to examine brain nicotine receptors in evaluating the role of a chemical called acetylcholine in memory and other problems in Parkinson's…
- Trial name
- NCT00058721
- Testing
- I-123-5-IA85380
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
Parkin Mutations and Their Functional Consequences
Parkinson's disease (PD) is the most frequent neurodegenerative disease with a prevalence of 2% over 65 years and because of this high prevalence as the population ages, it is a major problem of public health.
- Trial name
- NCT00136721
- Where
- France
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Parkinson Disease
Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study
This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.
- Trial name
- NCT07522606
- Testing
- BIA 28-6156
- Where
- 36 sites in United States, Italy and 3 more
- Sponsor
- Bial R&D Investments, S.A.
Stroke, Amyotrophic Lateral Sclerosis
Auto-calibrating System for Upper Limb Disability Assessment, Neurological and Occupational Rehabilitation
This interventional, multicenter, low-intervention clinical trial aims to evaluate the usability, feasibility, safety, and preliminary clinical impact of a robotic rehabilitation system designed for upper limb rehabilitation in…
- Conditions
- Stroke, Amyotrophic Lateral Sclerosis, PARKINSON DISEASE (Disorder), Mild Cognitive Impairment (MCI)
- Trial name
- ASULDAR (NCT07636538)
- Testing
- Auto-calibrating System for Upper Limb disability Assessment, neurological and occupational Rehabilitation, conventional therapy
- Volunteers
- 30 people
- Sponsor
- University of Pavia
Amyotrophic Lateral Sclerosis (ALS)
FHND1002 for ALS Treatment: Phase 2
This is a Phase II clinical trial evaluating the effectiveness and safety of an investigational drug, FHND1002 granules, in adults with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- FHN-ALS2 (NCT07138014)
- Testing
- FHND1002 100mg, FHND1002 200mg
- Volunteers
- 180 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Parkinson Disease, Pilates
Effect of Pilates Application on Abdominal Muscle Function, Core Stability, Musculoskeletal Pain, Quality of Life, Anxiety and Depression in Parkinson's Patients
In this study, it is aimed to investigate the effect of Pilates application on abdominal muscle function, core stability, musculoskeletal pain, quality of life, anxiety and depression in Parkinson's Patients.
- Conditions
- Parkinson Disease, Pilates, Muscle Function
- Trial name
- NCT04619784
- Testing
- Pilates Exercises, control
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Dokuz Eylul University
Parkinson Disease
Non-invasive Detection of Volatile Metabolites in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder. Currently, a diagnostic test for early PD does not exist.
- Trial name
- PANORAMA (NCT06453226)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Parkinson's Disease
Domperidone and Risk of Sudden Cardiac Death
The purpose of this study is to assess the risk of serious cardiac events, specifically ventricular tachyarrhythmia and sudden cardiac death (VT/SCD), associated with the use of domperidone in a population of patients with…
- Trial name
- NCT02500108
- Testing
- Domperidone
- Where
- Canada
- Volunteers
- 214,962 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Early Alzheimers Disease
Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
- Trial name
- NCT07496021
- Testing
- L. lactis CKDB001
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- CKD Bio Corporation
Parkinson's Disease (PD)
LFP-based Parameter Prediction in DBS for Parkinson's Disease
The goal of this observational study is to assess whether deep brain stimulation (DBS) contact selection in Parkinson's disease could be informed by subcortical local field potential (LFP) recordings.
- Trial name
- NCT07485621
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Loes Laurijssen
Parkinson Disease, Progression, Disease
Neuromelanin MRI: A Progression Marker in Early PD
Prospective observational study to qualify NM-MRI as progression marker in early Parkinson's.
- Trial name
- InsIghtPD (NCT05631158)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Canavan Disease, Infantile
Lithium and Acetate for Canavan Disease
The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.
- Conditions
- Canavan Disease, Infantile, Deficiency Disease, Aspartoacylase
- Trial name
- NCT00657748
- Testing
- Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moderate Alzheimer's Disease
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate Alzheimer's disease (AD).
- Trial name
- NCT03959553
- Testing
- GV1001, Normal saline
- Sponsor
- GemVax & Kael
Alzheimer Disease, Frontotemporal Degeneration
In Vivo PET of Synaptic Density in Cognitive Disorders
This study will compare the discriminative power of [18F]-SynVesT-1 PET and the standard-of-care [18F]-FDG PET in different cognitive disorders (Alzheimer's disease, Frontotemporal degeneration, dementia with Lewy bodies and…
- Conditions
- Alzheimer Disease, Frontotemporal Degeneration, Dementia With Lewy Bodies, Psychiatric Disorder
- Trial name
- NCT05384353
- Testing
- [18F]-SynVesT-1
- Where
- Belgium
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Parkinson's Disease, Mild Cognitive Impairment
A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease
This randomized, controlled trial (RCT) evaluates the benefits of memory and problem solving training compared to supportive therapy in individuals with Parkinson's Disease with Mild Cognitive Impairment (MCI) and their support…
- Trial name
- NCT01646333
- Testing
- Memory and Problem-Solving Intervention, Supportive Therapy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Virginia Commonwealth University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.